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As the balance of evidence regarding the protec-
tive effect of Bacillus Calmette-Guérin (BCG)
vaccination for tuberculosis disease/infection
shifts between the positive and the negative in
the past 100 years,1,2 BCG vaccination is still a
major strategy of national tuberculosis control
policy in most of countries following the recom-
mendation of World Health Organization (WHO).
In areas with a moderate tuberculosis burden, the
national vaccination program usually includes
BCG at birth to protect infants from meningitis
and disseminated tuberculosis. The WHO reported
a BCG coverage rate >80% for neonates and in-
fants in countries where it was included in the
national childhood immunization program.3
National BCG vaccination has been launched for
use in infants in Taiwan since 1965. The coverage
rate increased to 87% in 1975 and has remained
above 97% since 2001.4,5
A number of BCG vaccine strains are avail-
able, with the French Pasteur strain 1173 P2, the
Danish strain 1331, the Glaxo strain 1077 and
the Tokyo strain 172 accounting for about 90%
of BCG vaccinations worldwide.3 In terms of effi-
cacy, no BCG strain is demonstrably better than
another, and there is no global consensus as to
which BCG strain is optimal for general use. The
Pasteur strain was initially used when the BCG
vaccination program was initiated in Taiwan
back in the 1960s. The strain was then changed
to the less reactogenic Tokyo 172 related strain
due to the concern of axillary lymphadenitis in
1979.4
The protective effect of BCG in Taiwan can be
demonstrated in three different ways. The Figure
reveals the correlation between tuberculosis-related
mortality in young children and the coverage
rate of BCG vaccination in infancy. Before 1965,
the mortality rate of extrapulmonary tuberculo-
sis in children younger than 5 years was over
10/100,000 person-year. Meanwhile, the mortality
rate of pulmonary tuberculosis in children at the
same age was over 4/100,000 person-year. As the
coverage rate scaled up sharply from zero to
70–80% during 1965–1970, the mortality rates
halved, for both extrapulmonary and pulmonary
tuberculosis in this age group. In the following
20 years, the mortality of extrapulmonary tuber-
culosis declined sharply, almost 100-fold from
10/100,000 in 1965 to 0.1/100,000 in 1985.
The second aspect is to compare the incidence
of childhood tuberculosis in Taiwan to those in
other developed countries. For example, in USA,
the incidence of adult tuberculosis was around
8–12/100,000 person-year during 1993–2001 and
was 4–6/100,000 in children younger than 5 years.6
In Taiwan, the incidence of adult tuberculosis
was 70/100,000 person-year, which was 10 times
that in the USA. Tuberculosis incidence in chil-
dren younger than 5 years in Taiwan was below
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5/100,000 person-year during 1996–2003, which
was almost equal to the corresponding incidence
in the US.7 The reason for this discrepancy of
comparative incidences in adults and children
can best be explained by the fact that almost all
neonates in Taiwan receive BCG vaccinations,5
which can protect children younger than 5 years
of age from tuberculosis.
The third aspect is from the view of the odds
of tuberculosis meningitis of BCG vaccinated
versus BCG unvaccinated children. The number
of live births during 2002–2007 was estimated to
be 1,290,000, and the coverage rate of BCG vac-
cination in infancy was 97% during that period.
Twelve cases of tuberculosis meningitis were no-
tified during 2002–2007, and four of them were
in BCG unvaccinated children. Thus, the risk of
tuberculosis meningitis in BCG unvaccinated
children was 16 times higher than in BCG vacci-
nated children, with a 95% confidence interval of
4.9–53.7. The protective effect of BCG is obvious.
Two recently published meta-analyses con-
cerning the efficacy of BCG vaccination for tu-
berculosis prevention shed light on the vaccine’s
protective efficacy.8,9 The first meta-analysis in-
cluded data from 10 randomized clinical trials
and eight case-controlled studies published since
1950.8 The results of this analysis indicated an
86% protective effect of BCG against meningeal
and miliary tuberculosis in children in clinical
trials. It also showed that the protective efficacies
of BCG against pulmonary tuberculosis differed
significantly among these 18 studies to preclude
the estimation of a summary protective efficacy
rate. The second meta-analysis reviewed the results
of 14 clinical trials and 12 case-controlled studies,9
using a random-effects regression model to ex-
plore the sources of the heterogeneity in the effi-
cacy of the BCG vaccine reported in the individual
studies. Using a model that included the geo-
graphic latitude of the study site and the data 
validity score as covariates, they estimated the
overall protective effect of BCG vaccine to be 51%
in the clinical trials (95% CI, 30–66%) and 50%
in the case-controlled studies (95% CI, 36–61%).
In recent years, there has been a dramatic in-
crease in the number of candidate tuberculosis
vaccines evaluated in research laboratories. Better
understanding of the immunologic deficits of
BCG and impressive progress in knowledge of
mycobacterial genomics have paved the way for
promising new products, e.g. MVA85 A, a booster-
based subunit vaccine now in phase II trials in
the Western cape of South Africa.10
In conclusion, BCG is currently the only avail-
able vaccine for tuberculosis before the new can-
didate vaccines become “real”. From the experience
in Taiwan, several lines of evidence support the
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Figure.Mortality due to pulmonary tuberculosis (TB) and extrapulmonary TB in children younger than 5 years of age and
coverage rate of Bacillus Calmette-Guérin (BCG) vaccination in infancy for the years 1956–1987 in Taiwan.
effectiveness of neonatal BCG vaccination in pro-
tecting young children from tuberculosis, espe-
cially severe forms of tuberculosis infection such
as tuberculosis meningitis and related death. How-
ever, further studies are needed to determine its
cost-effectiveness on which most policy-making
is based.
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